+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA



Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA



Respiratory Medicine 139: 65-71



Improved outcomes have been reported for patients with chronic obstructive pulmonary disease (COPD) receiving combination long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) therapy compared with LAMA monotherapy. However, little is known about the relative characteristics of these patients and their rates of escalation to triple therapy (TT, combining a LAMA, LABA, and inhaled corticosteroid). This study aimed to characterize patients initiating treatment with the LAMA tiotropium (TIO) and the fixed-dose LAMA/LABA combination therapy umeclidinium/vilanterol (UMEC/VI), and to compare rates of escalation to TT between patients receiving these therapies. Retrospective study of patients with COPD enrolled in a US health insurance plan during 2013-2015 and newly initiated on TIO or UMEC/VI. Patients were ≥40 years of age at index (date of therapy initiation) with continuous enrollment for 12 months pre-index and ≥30 days post-index. LAMA users were propensity score matched 1:1 to LAMA/LABA users, with TT initiation rates reported by cohort using pharmacy claims. 35,357 patients initiating on TIO and 2407 patients initiating on UMEC/VI were identified. After propensity score matching, the rate of TT initiation was significantly higher in new TIO users (n = 1320) than in new UMEC/VI users (n = 1320) (0.92 vs 0.49 per 100 months of exposure, respectively; p < 0.001). Relative to the UMEC/VI cohort, the TIO cohort had an 87% higher risk of TT initiation (hazard ratio: 1.87; 95% confidence interval: 1.4-2.5; p = 0.001). Patients receiving UMEC/VI progressed to TT more slowly, and were at lower risk of progressing to TT, than patients receiving TIO.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065459779

Download citation: RISBibTeXText

PMID: 29858004

DOI: 10.1016/j.rmed.2018.04.014


Related references

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. International Journal of Chronic Obstructive Pulmonary Disease 14: 531-546, 2019

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 12: 907-922, 2017

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13: 3203-3231, 2018

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box. Erj Open Research 5(1):, 2019

Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study. Managed Care 27(5): 40-47, 2018

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. International Journal of Chronic Obstructive Pulmonary Disease 13: 3971-3981, 2018

Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. Chest 155(4): 758-770, 2019

P59Factors influencing step-up to lama+laba/ics in Copd patients initially on lama monotherapy: a thin database study. Thorax 71(Suppl 3): A116.1-A116, 2016

Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study. Respiratory Medicine 142: 73-80, 2018

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17(5): 509-517, 2018

The Overrated Impact of Inhaled Substances (LABA, LAMA, ICS) on Exacerbation Rates in COPD. Pneumologie 72(2): 132-137, 2018

The Overrated Impact of Inhaled Substances (LABA, LAMA, ICS) on Exacerbation Rates in COPD. Pneumologie 72(2): E1, 2018

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. International Journal of Chronic Obstructive Pulmonary Disease 10: 1093-1102, 2015

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. International Journal of Chronic Obstructive Pulmonary Disease 11: 785-797, 2016

Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest 155(6): 1158-1165, 2019